IS6623A - Ný kristölluð og myndlaus form af tríasól(4,5-D)pýrimídínefnasambandi - Google Patents

Ný kristölluð og myndlaus form af tríasól(4,5-D)pýrimídínefnasambandi

Info

Publication number: IS6623A
Authority: IS; Iceland
Prior art keywords: triazole; amorphous form; pyrimidine compound; new crystalline; crystalline
Prior art date: 2000-06-02

Application number

IS6623A

Other languages

English (en)

Other versions

IS2609B (is

Inventor

Bohlin Martin

Cosgrove Steve

Lassen Bo

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-02

Filing date

2002-11-15

Publication date

2002-11-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9892841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS6623(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-11-15 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2002-11-15 Publication of IS6623A publication Critical patent/IS6623A/is

2010-04-15 Publication of IS2609B publication Critical patent/IS2609B/is

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Surgery (AREA)
Oncology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

IS6623A 2000-06-02 2002-11-15 Ný kristölluð form efnasambands (1S-(1a, 2a, 3B(1S*, 2R*), 5B))-3-(7-((2-(2,4-díflúorófenýl)sýklóprópýl)amínó)-5-(próýlþíó)-3H-1,2,3-tríazóló(4,5-d)pýrimídín-3-ýl)-5-(2-hýdróxýetoxý)sýklópentan-1,2-díól IS2609B (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0013407.2A GB0013407D0 (en)	2000-06-02	2000-06-02	Forms of a chemical compound
PCT/SE2001/001239 WO2001092262A1 (en)	2000-06-02	2001-05-31	New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound

Publications (2)

Publication Number	Publication Date
IS6623A true IS6623A (is)	2002-11-15
IS2609B IS2609B (is)	2010-04-15

Family

ID=9892841

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IS6623A IS2609B (is)	2000-06-02	2002-11-15	Ný kristölluð form efnasambands (1S-(1a, 2a, 3B(1S, 2R), 5B))-3-(7-((2-(2,4-díflúorófenýl)sýklóprópýl)amínó)-5-(próýlþíó)-3H-1,2,3-tríazóló(4,5-d)pýrimídín-3-ýl)-5-(2-hýdróxýetoxý)sýklópentan-1,2-díól
IS8825A IS3019B (is)	2000-06-02	2009-06-02	Ný kristölluð og myndlaus form af tríasól(4,5-D)pýrímídínefnasambandi

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IS8825A IS3019B (is)	2000-06-02	2009-06-02	Ný kristölluð og myndlaus form af tríasól(4,5-D)pýrímídínefnasambandi

Country Status (36)

Country	Link
US (3)	US20030181469A1 (is)
EP (3)	EP2292622A1 (is)
JP (3)	JP5036947B2 (is)
KR (1)	KR100781864B1 (is)
CN (2)	CN1817883B (is)
AR (2)	AR032335A1 (is)
AT (2)	ATE555115T1 (is)
AU (4)	AU2001262874B2 (is)
BG (3)	BG65837B1 (is)
BR (1)	BR0111328A (is)
CA (1)	CA2408596C (is)
CY (1)	CY1113047T1 (is)
CZ (2)	CZ307468B6 (is)
DE (1)	DE60117972T2 (is)
DK (2)	DK1493745T3 (is)
EE (1)	EE05222B1 (is)
ES (2)	ES2259031T3 (is)
GB (1)	GB0013407D0 (is)
HK (1)	HK1052347B (is)
HU (2)	HU229374B1 (is)
IL (4)	IL152777A0 (is)
IS (2)	IS2609B (is)
MX (1)	MXPA02011795A (is)
MY (2)	MY148652A (is)
NO (3)	NO323780B1 (is)
NZ (1)	NZ522638A (is)
PH (1)	PH12011000127A1 (is)
PL (2)	PL392882A1 (is)
PT (2)	PT1289992E (is)
RU (3)	RU2325391C2 (is)
SG (1)	SG135965A1 (is)
SI (2)	SI1493745T1 (is)
SK (1)	SK287817B6 (is)
UA (1)	UA73181C2 (is)
WO (1)	WO2001092262A1 (is)
ZA (1)	ZA200209324B (is)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI229674B (en)	1998-12-04	2005-03-21	Astra Pharma Prod	Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
GB0013407D0 (en)	2000-06-02	2000-07-26	Astrazeneca Ab	Forms of a chemical compound
GB0013488D0 (en) *	2000-06-02	2000-07-26	Astrazeneca Ab	Chemical compound
JP4298212B2 (ja) *	2002-03-29	2009-07-15	大日本印刷株式会社	塩酸エピナスチン高融点型結晶の製造法
WO2008024044A1 (en) *	2006-08-21	2008-02-28	Astrazeneca Ab	Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate
TWI482772B (zh)	2006-08-21	2015-05-01	Astrazeneca Ab	適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
JP2010508350A (ja) *	2006-10-31	2010-03-18	ヤンセンファーマシューティカエヌ．ベー．	Ａｄｐｐ２ｙ１２レセプターアンタゴニストとしてのトリアゾロピリミジン誘導体
JP5469595B2 (ja) *	2007-04-13	2014-04-16	ミレニアムファーマシューティカルズ，インコーポレイテッド	第Ｘａ因子阻害薬として作用する化合物との併用抗凝固療法
TWI496776B (zh) *	2007-11-15	2015-08-21	Astrazeneca Ab	製備(3aR,4S,6R,6aS)-6-胺基-2,2-二甲基四氫-3aH-環戊并[d][1,3]二氧雜環戊烯-4-醇之純非對映異構性之二苯甲醯-L-酒石酸鹽之方法
UA100864C2 (uk) *	2007-12-03	2013-02-11	Астразенека Аб	Спосіб лікування або запобігання аневризмі черевної аорти
CA2734454C (en)	2008-09-09	2016-09-13	Astrazeneca Ab	A process for preparing [1s-[1-alpha,2-alpha,3-beta(1s,2r)5-beta]]-3-[7-[2-(3,4-difluorophenyl)-cyclopropylamino]-5-(propylthio)-3h-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol and to its intermediates
EP2459564B1 (en)	2009-07-27	2016-09-07	Auspex Pharmaceuticals, Inc.	Cyclopropyl modulators of p2y12 receptor
EP2507242A1 (en) *	2009-12-03	2012-10-10	AstraZeneca AB	Co - crystals of a triazolo [4,5 - d]pyrimidine platelet aggregation inhibitor
EA026094B1 (ru) *	2009-12-23	2017-03-31	Рациофарм Гмбх	Твердая лекарственная форма тикагрелора
CZ2011229A3 (cs) *	2011-04-19	2012-08-15	Zentiva, K.S.	Opticky aktivní soli (3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyklopenta-[d][1,3]dioxol-4-olu a zpusob jejich prípravy
JP2014516982A (ja)	2011-06-01	2014-07-17	アストラゼネカアクチボラグ	新規なチカグレロル共結晶
MX2014006190A (es) *	2011-11-30	2014-07-10	Actavis Group Ptc Ehf	Nueva forma cristalina de ticagrelor y proceso para la preparacion de la misma.
EP2834247A4 (en)	2012-04-05	2016-03-30	Reddys Lab Ltd Dr	PREPARATION OF TICAGRELOR
WO2014000719A1 (en) *	2012-06-29	2014-01-03	Zentiva, K.S.	Novel pharmaceutical solid forms of (1s,2s,3r,5s)-3-[7-[(1r,2s)-2-(3,4difluorophenyl)cyclopropylamino]-5-(propylthio)-3h-[1,2,3]triazolo[4,5-d]pyrimidin-3yl]-5-(2-hydroxyethoxy)cyclopentane-l,2-diol
CA2877541C (en)	2012-07-04	2020-06-30	Lek Pharmaceuticals D.D.	Ticagrelor adducts with divalent metal salts
CZ2012705A3 (cs) *	2012-10-16	2014-04-23	Zentiva, K.S.	Pevná orální farmaceutická formulace obsahující ticagrelor
CN103772393B (zh) *	2012-10-18	2017-08-04	博瑞生物医药（苏州）股份有限公司	替卡格雷的晶型及其制备方法
WO2014083139A1 (en) *	2012-11-29	2014-06-05	Actavis Group Ptc Ehf	Novel amorphous form of ticagrelor
CN103848836B (zh) *	2012-12-07	2016-08-03	天津市汉康医药生物技术有限公司	替卡格雷倍半水合物及其制备方法
WO2014118808A2 (en) *	2013-02-04	2014-08-07	Hetero Research Foundation	Ticagrelor solid dispersion
CZ307217B6 (cs)	2013-03-14	2018-04-04	Zentiva, K.S.	Zlepšený způsob výroby a nové intermediáty syntézy ticagreloru
WO2014155389A2 (en) *	2013-03-25	2014-10-02	Glenmark Pharmaceuticals Limited; Glenmark Generics Limited	Process for preparation of ticagrelor
CN104098570A (zh) *	2013-04-07	2014-10-15	杭州领业医药科技有限公司	替卡格雷晶型及其制备方法和用途
CN104098572A (zh) *	2013-04-08	2014-10-15	博瑞生物医药技术(苏州)有限公司	替卡格雷共晶型
CN107573333B (zh) *	2013-04-10	2019-10-18	江苏恒瑞医药股份有限公司	替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
WO2014170026A1 (en)	2013-04-18	2014-10-23	Zentiva, K.S.	Stabilized amorphous ticagrelor
EP2813216A1 (en)	2013-06-10	2014-12-17	Zentiva, a.s.	Stabilized amorphous ticagrelor
EA201501164A1 (ru)	2013-05-29	2016-08-31	Рациофарм Гмбх	Твердая фармацевтическая лекарственная форма
CN106496235A (zh) *	2013-06-03	2017-03-15	杭州领业医药科技有限公司	结晶形态的三唑[4,5‑d]嘧啶化合物及其制备方法和用途
EP3004113A2 (en) *	2013-06-04	2016-04-13	Dr. Reddy's Laboratories Ltd.	Preparation of ticagrelor
EP2816043A1 (en)	2013-06-21	2014-12-24	LEK Pharmaceuticals d.d.	Spherical ticagrelor particles
WO2015001489A1 (en) *	2013-07-01	2015-01-08	Ranbaxy Laboratories Limited	Pharmaceutical compositions of ticagrelor
CN104341423B (zh) *	2013-08-02	2017-03-01	上海京新生物医药有限公司	替格瑞洛的一水合物及其制备方法与在制药中的应用
CN104370912A (zh) *	2013-08-13	2015-02-25	开原亨泰制药股份有限公司	替卡格雷多晶型体及其制备方法
IN2013CH04023A (is) *	2013-09-10	2015-08-07	Laurus Labs Pvt Ltd
CZ2013866A3 (cs)	2013-11-08	2015-05-20	Zentiva, K.S.	Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru
CN104650085A (zh) *	2013-11-22	2015-05-27	天津市汉康医药生物技术有限公司	替卡格雷倍半水合物化合物
CN103601726B (zh) *	2013-12-02	2016-09-28	浙江大学	两种替格瑞洛药物共晶及其制备方法
CN104710425B (zh) *	2013-12-16	2019-06-14	石药集团中奇制药技术（石家庄）有限公司	一种替格瑞洛新结晶及其制备方法
CN104650091B (zh) *	2014-01-24	2016-10-05	福州乾正药业有限公司	替格瑞洛的微粉化及其晶型，以及制备方法和药物应用
CN104940204A (zh) *	2014-03-27	2015-09-30	广东东阳光药业有限公司	一种替格瑞洛固体制剂及其制备方法
WO2015162537A1 (en) *	2014-04-23	2015-10-29	Glenmark Pharmaceuticals Limited; Glenmark Generics Limited	Process for preparation of ticagrelor
WO2015162630A1 (en)	2014-04-25	2015-10-29	Anlon Chemical Research Organization	Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis.
CN105315282B (zh) *	2014-07-15	2018-09-21	博瑞生物医药（苏州）股份有限公司	一种制备替卡格雷无定型的方法
WO2016016907A1 (en) *	2014-08-01	2016-02-04	Msn Laboratories Private Limited	Novel polymorphs of (1s,2s,3r,5s)-3-[7-{[(1r,2s)-2-(3,4-difluorophenyl) cyclopropyl]amino}-5-(propylthio)-3h-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yi]-5-(2-hydroxvethoxy) cyclopentane-1,2-diol
US10017515B2 (en)	2014-08-11	2018-07-10	Sun Pharmaceutical Industries Limited	Stable amorphous ticagrelor and a process for its preparation
CN104193747B (zh) *	2014-08-12	2016-05-11	许彩霞	替卡格雷无定形的制备
WO2016116942A1 (en)	2015-01-20	2016-07-28	Anlon Chemical Research Organization	Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
CN105968113B (zh) *	2015-03-12	2019-06-07	四川海思科制药有限公司	一种三唑并嘧啶衍生物及其应用
WO2017072790A1 (en) *	2015-10-26	2017-05-04	Avra Laboratories Pvt. Ltd.	An improved process for synthesis of ticagrelor
US20190002471A1 (en) *	2016-01-05	2019-01-03	Amneal Pharmaceuticals Company Gmbh	Crystalline Form Of Ticagrelor
CN107595789B (zh)	2016-04-21	2021-01-15	阿斯利康(瑞典)有限公司	口腔崩解片
US10905691B2 (en)	2016-09-09	2021-02-02	Université de Liège	Use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection
EP3292867B1 (en) *	2016-09-09	2019-05-15	Université de Liège	Triazolo(4,5-d)pyrimidine derivatives for use in the prevention and treatment of bacterial infection
KR101916956B1 (ko)	2016-12-13	2018-11-08	보령제약 주식회사	티카그렐러의 신규한 고체 형태 및 이의 제조방법
WO2018178997A1 (en)	2017-03-31	2018-10-04	Natco Pharma Limited	Novel crystalline form of ticagrelor
WO2019127294A1 (zh) *	2017-12-29	2019-07-04	浙江天宇药业股份有限公司	一种纯化替格瑞洛的方法
EP3761965A1 (en)	2018-03-08	2021-01-13	Pharmaceutical Oriented Services Ltd	Ticagrelor-containing tablet formulation
SI3829547T1 (sl)	2018-07-27	2025-10-30	Krka, D.D., Novo Mesto	Farmacevtska sestava tikagrelorja
CN110194771A (zh) *	2019-05-08	2019-09-03	北京济美堂医药研究有限公司	一种替格瑞洛药用ii晶型的制备方法
CN114634489B (zh) *	2022-04-19	2023-07-04	奎马特里克斯有限公司	结晶形式
CN117510508A (zh) *	2023-11-14	2024-02-06	江苏普润生物医药有限公司	一种高纯度ii晶型替格瑞洛的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5561134A (en) *	1990-09-25	1996-10-01	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
FR2687677B1 (fr) *	1992-02-24	1996-10-11	Union Pharma Scient Appl	Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant.
PL182680B1 (pl) *	1995-07-11	2002-02-28	Astrazeneca Ab	Nowe inhibitory skupiania się płytek krwi
AU5501598A (en) *	1996-12-20	1998-07-17	Astra Pharmaceuticals Limited	Triazolo{4,5-(d)}pyrimidinyl derivatives and their use as medicaments
AR017014A1 (es)	1997-07-22	2001-08-22	Astrazeneca Ab	Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
PT1243590E (pt) *	1997-07-25	2005-05-31	Gilead Sciences Inc	Composicao de analogos nuclotidicos e metodo de sintese
TWI229674B (en) *	1998-12-04	2005-03-21	Astra Pharma Prod	Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9904129D0 (sv) *	1999-11-15	1999-11-15	Astra Pharma Prod	Novel compounds
GB0013488D0 (en) *	2000-06-02	2000-07-26	Astrazeneca Ab	Chemical compound
GB0013407D0 (en)	2000-06-02	2000-07-26	Astrazeneca Ab	Forms of a chemical compound

2000
- 2000-06-02 GB GBGB0013407.2A patent/GB0013407D0/en not_active Ceased
2001
- 2001-05-22 AR ARP010102432A patent/AR032335A1/es unknown
- 2001-05-31 CA CA2408596A patent/CA2408596C/en not_active Expired - Lifetime
- 2001-05-31 DK DK04015299.3T patent/DK1493745T3/da active
- 2001-05-31 SG SG200500599-6A patent/SG135965A1/en unknown
- 2001-05-31 AU AU2001262874A patent/AU2001262874B2/en not_active Expired
- 2001-05-31 MY MYPI20092026A patent/MY148652A/en unknown
- 2001-05-31 IL IL15277701A patent/IL152777A0/xx unknown
- 2001-05-31 HU HU0302284A patent/HU229374B1/hu unknown
- 2001-05-31 WO PCT/SE2001/001239 patent/WO2001092262A1/en not_active Ceased
- 2001-05-31 EP EP10182133A patent/EP2292622A1/en not_active Withdrawn
- 2001-05-31 KR KR1020027016379A patent/KR100781864B1/ko not_active Ceased
- 2001-05-31 ES ES01937109T patent/ES2259031T3/es not_active Expired - Lifetime
- 2001-05-31 CZ CZ2012-293A patent/CZ307468B6/cs not_active IP Right Cessation
- 2001-05-31 EP EP01937109A patent/EP1289992B1/en not_active Expired - Lifetime
- 2001-05-31 DE DE60117972T patent/DE60117972T2/de not_active Expired - Lifetime
- 2001-05-31 AT AT04015299T patent/ATE555115T1/de active
- 2001-05-31 HU HU1300386A patent/HU230471B1/hu unknown
- 2001-05-31 HK HK03104536.0A patent/HK1052347B/en not_active IP Right Cessation
- 2001-05-31 EP EP04015299.3A patent/EP1493745B2/en not_active Expired - Lifetime
- 2001-05-31 MX MXPA02011795A patent/MXPA02011795A/es active IP Right Grant
- 2001-05-31 AU AU6287401A patent/AU6287401A/xx active Pending
- 2001-05-31 BR BR0111328-3A patent/BR0111328A/pt not_active Application Discontinuation
- 2001-05-31 PL PL392882A patent/PL392882A1/pl not_active Application Discontinuation
- 2001-05-31 PL PL01359172A patent/PL359172A1/xx not_active IP Right Cessation
- 2001-05-31 ES ES04015299T patent/ES2384708T3/es not_active Expired - Lifetime
- 2001-05-31 EE EEP200200665A patent/EE05222B1/xx unknown
- 2001-05-31 SI SI200131013T patent/SI1493745T1/sl unknown
- 2001-05-31 PT PT01937109T patent/PT1289992E/pt unknown
- 2001-05-31 NZ NZ522638A patent/NZ522638A/en not_active IP Right Cessation
- 2001-05-31 RU RU2002135589/04A patent/RU2325391C2/ru active
- 2001-05-31 UA UA20021210808A patent/UA73181C2/uk unknown
- 2001-05-31 MY MYPI20012578A patent/MY140674A/en unknown
- 2001-05-31 US US10/296,990 patent/US20030181469A1/en not_active Abandoned
- 2001-05-31 JP JP2002500875A patent/JP5036947B2/ja not_active Expired - Lifetime
- 2001-05-31 SK SK1685-2002A patent/SK287817B6/sk not_active IP Right Cessation
- 2001-05-31 CZ CZ2002-3918A patent/CZ304347B6/cs not_active IP Right Cessation
- 2001-05-31 DK DK01937109T patent/DK1289992T3/da active
- 2001-05-31 PT PT04015299T patent/PT1493745E/pt unknown
- 2001-05-31 SI SI200130541T patent/SI1289992T1/sl unknown
- 2001-05-31 CN CN2006100025095A patent/CN1817883B/zh not_active Expired - Lifetime
- 2001-05-31 AT AT01937109T patent/ATE320430T1/de active
- 2001-05-31 CN CNB018105823A patent/CN1247583C/zh not_active Expired - Lifetime
2002
- 2002-11-11 IL IL152777A patent/IL152777A/en active IP Right Grant
- 2002-11-15 IS IS6623A patent/IS2609B/is unknown
- 2002-11-15 ZA ZA200209324A patent/ZA200209324B/en unknown
- 2002-11-28 BG BG107331A patent/BG65837B1/bg unknown
- 2002-11-29 NO NO20025756A patent/NO323780B1/no not_active IP Right Cessation
2005
- 2005-08-30 RU RU2005127356/04A patent/RU2418802C2/ru active Protection Beyond IP Right Term
- 2005-10-03 US US11/240,801 patent/US7265124B2/en not_active Expired - Lifetime
2007
- 2007-03-05 AU AU2007200958A patent/AU2007200958B2/en active Active
- 2007-03-23 NO NO20071547A patent/NO332306B1/no not_active IP Right Cessation
- 2007-08-24 US US11/892,597 patent/US20070293513A1/en not_active Abandoned
- 2007-11-19 IL IL187482A patent/IL187482A/en active IP Right Grant
2008
- 2008-07-24 AR ARP080103205A patent/AR068086A2/es unknown
2009
- 2009-06-02 IS IS8825A patent/IS3019B/is unknown
- 2009-08-12 BG BG10110440A patent/BG66332B1/bg unknown
- 2009-12-07 IL IL202582A patent/IL202582A/en active IP Right Grant
2010
- 2010-12-10 RU RU2010150799/04A patent/RU2010150799A/ru not_active Application Discontinuation
- 2010-12-24 AU AU2010257449A patent/AU2010257449B2/en not_active Expired
2011
- 2011-04-19 PH PH12011000127A patent/PH12011000127A1/en unknown
- 2011-08-18 BG BG10111017A patent/BG111017A/bg unknown
2012
- 2012-05-01 JP JP2012104575A patent/JP5684192B2/ja not_active Expired - Lifetime
- 2012-05-14 NO NO20120595A patent/NO333289B1/no not_active IP Right Cessation
- 2012-06-21 CY CY20121100559T patent/CY1113047T1/el unknown
2014
- 2014-04-07 JP JP2014078665A patent/JP2014129423A/ja active Pending

Also Published As

Publication number	Publication date
JP5684192B2 (ja)	2015-03-11
NO333289B1 (no)	2013-04-29
AU2001262874B2 (en)	2007-03-22
CN1247583C (zh)	2006-03-29
JP2012149093A (ja)	2012-08-09
CZ307468B6 (cs)	2018-09-26
IL187482A (en)	2010-06-16
IL152777A (en)	2008-11-26
DE60117972T2 (de)	2006-11-23
EP1289992A1 (en)	2003-03-12
CN1432018A (zh)	2003-07-23
HUP0302284A2 (hu)	2003-10-28
HU229374B1 (en)	2013-11-28
KR20030007829A (ko)	2003-01-23
IL202582A (en)	2012-12-31
ZA200209324B (en)	2004-02-16
IS8825A (is)	2009-06-02
JP2003535092A (ja)	2003-11-25
ES2384708T3 (es)	2012-07-11
BG65837B1 (bg)	2010-02-26
PH12011000127A1 (en)	2016-08-31
ATE555115T1 (de)	2012-05-15
BR0111328A (pt)	2003-06-10
SG135965A1 (en)	2007-10-29
CN1817883B (zh)	2011-10-05
RU2010150799A (ru)	2012-06-20
KR100781864B1 (ko)	2007-12-05
CY1113047T1 (el)	2016-04-13
UA73181C2 (en)	2005-06-15
RU2005127356A (ru)	2007-03-10
NO20025756L (no)	2003-01-24
BG110440A (bg)	2010-03-31
CZ20120293A3 (is)	2003-07-16
SK16852002A3 (sk)	2003-08-05
JP5036947B2 (ja)	2012-09-26
AU2007200958B2 (en)	2010-10-07
ATE320430T1 (de)	2006-04-15
NZ522638A (en)	2004-06-25
JP2014129423A (ja)	2014-07-10
EP1493745B1 (en)	2012-04-25
SI1493745T1 (sl)	2012-08-31
HK1052347B (en)	2006-09-08
MXPA02011795A (es)	2003-04-10
IL152777A0 (en)	2003-06-24
NO20025756D0 (no)	2002-11-29
AU2007200958A1 (en)	2007-03-29
EP1493745B2 (en)	2021-05-19
CN1817883A (zh)	2006-08-16
SI1289992T1 (sl)	2006-08-31
RU2418802C2 (ru)	2011-05-20
NO20071547L (no)	2003-01-24
IS3019B (is)	2020-02-15
EE05222B1 (et)	2009-10-15
HUP0302284A3 (en)	2007-05-29
BG111017A (bg)	2011-12-30
CZ304347B6 (cs)	2014-03-19
EP2292622A1 (en)	2011-03-09
US20070173518A1 (en)	2007-07-26
ES2259031T3 (es)	2006-09-16
AR068086A2 (es)	2009-11-04
HK1073101A1 (en)	2005-09-23
AR032335A1 (es)	2003-11-05
CA2408596C (en)	2010-12-21
HUP1300386A2 (en)	2003-10-28
US7265124B2 (en)	2007-09-04
DK1289992T3 (da)	2006-07-03
IS2609B (is)	2010-04-15
NO323780B1 (no)	2007-07-02
IL202582A0 (en)	2010-06-30
HK1052347A1 (en)	2003-09-11
MY148652A (en)	2013-05-15
MY140674A (en)	2010-01-15
EP1289992B1 (en)	2006-03-15
EP1493745A1 (en)	2005-01-05
DK1493745T3 (da)	2012-07-16
US20030181469A1 (en)	2003-09-25
AU2010257449B2 (en)	2012-03-22
EE200200665A (et)	2004-06-15
AU6287401A (en)	2001-12-11
NO332306B1 (no)	2012-08-20
PT1289992E (pt)	2006-07-31
WO2001092262A1 (en)	2001-12-06
PL392882A1 (pl)	2011-03-14
US20070293513A1 (en)	2007-12-20
CA2408596A1 (en)	2001-12-06
GB0013407D0 (en)	2000-07-26
SK287817B6 (sk)	2011-11-04
BG66332B1 (bg)	2013-06-28
BG107331A (bg)	2003-07-31
NO20120595L (no)	2003-01-24
RU2325391C2 (ru)	2008-05-27
PL359172A1 (en)	2004-08-23
HU230471B1 (hu)	2016-07-28
DE60117972D1 (de)	2006-05-11
AU2010257449A1 (en)	2011-01-20
PT1493745E (pt)	2012-06-28

Publication	Publication Date	Title
IS8825A (is)	2009-06-02	Ný kristölluð og myndlaus form af tríasól (4,5-D) pýrimídínefnasambandi
PL369530A1 (en)	2005-05-02	Chemical compounds
MXPA02011977A (es)	2003-04-22	Herbicidas de piridina sustituidas.
GB0123589D0 (en)	2001-11-21	Organic compounds
MY134892A (en)	2007-12-31	Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
PH12009501118A1 (en)	2014-05-12	Chemical compounds
GB0124627D0 (en)	2001-12-05	Novel compounds
WO2002048147A3 (en)	2003-03-27	Pyrazolopyridines
MY137774A (en)	2009-03-31	Acetylene derivatives having mglur5 antagonistic activity
WO2004074244A3 (en)	2004-11-11	Pyrimidine compounds
WO2003095455A3 (en)	2003-12-24	Substituted pyrazolopyrimidines
DK1522539T3 (da)	2007-05-07	Krystallinsk komposition indeholdende excitalopram
TR200002380T2 (tr)	2001-03-21	Yeni triazolo (4,5-d) pirimidin bileşikleri
WO2002085291A3 (en)	2003-02-20	Nociceptin analogs
ZA200309100B (en)	2005-02-28	Exothermic formulations for the treatment of ectoparasites.
MXPA04003755A (es)	2004-07-23	Endoprotesis vasculares.
CA2452036A1 (en)	2003-01-09	6-'2-(phosphonomethoxy) alkoxy pyrimidine derivatives having antiviral activity
ATE251162T1 (de)	2003-10-15	Triazolo(4,5-d)pyrimidin-verbindungen
MXPA02012400A (es)	2004-05-03	Heterociclos hetaril-substituidos.
SE9904128D0 (sv)	1999-11-15	Novel compounds
DK1338596T3 (da)	2006-04-18	Fremgangsmåde til fremstilling af antibakterielt middel af carbapenemtypen
DE69900297D1 (de)	2001-10-25	Akarizid und insektizid wirksame, substituierte Pyrimidine und Verfahren zu ihrer Herstellung
MX9701569A (es)	1997-05-31	Pirimidin(tio)onas substituidas.
BRPI0206922B8 (pt)	2016-05-10	composto de fragrância, composição de fragrância contendo o mesmo, e método para preparação de um composto de fragrância
DK1328275T3 (da)	2008-09-01	Substituerede 4,5-dihydro-1,2,4-triazin-3-oner, 1,2,4-triazin-3-oner og deres anvendelse som fungicider og insekticider